The effect of ivabradine on hospitalization of heart failure patients: A retrospective cohort study
Background: Ivabradine is recommended in heart failure (HF) patients to reduce cardiovascular death and hospitalization due to worsening of HF symptoms. Aims and Objectives: To study the effect of Ivabradine in addition to guideline-directed medical therapy (GDMT) in a group of HF patients with HR m...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Heart Views |
| Subjects: | |
| Online Access: | http://www.heartviews.org/article.asp?issn=1995-705X;year=2021;volume=22;issue=3;spage=165;epage=173;aulast=Al-Balushi |
| _version_ | 1819001603482451968 |
|---|---|
| author | Sara Al-Balushi Mohammed Fasihul Alam Abdul Rehman Abid Amal Sharfi |
| author_facet | Sara Al-Balushi Mohammed Fasihul Alam Abdul Rehman Abid Amal Sharfi |
| author_sort | Sara Al-Balushi |
| collection | DOAJ |
| description | Background: Ivabradine is recommended in heart failure (HF) patients to reduce cardiovascular death and hospitalization due to worsening of HF symptoms.
Aims and Objectives: To study the effect of Ivabradine in addition to guideline-directed medical therapy (GDMT) in a group of HF patients with HR more than 70 bpm, HF with reduced ejection fraction (HFrEF) left ventricular ejection fraction (LVEF ≤ 40%), and New York Heart Association class II-IV.
Methods: The study was conducted at Heart Hospital, Hamad Medical Corporation, Qatar. HF patients with age > 18 years, LVEF ≤40%, on GDMT, and HR of ≥70 bpm were included. The study population was divided into two groups: ivabradine group and non-ivabradine group. The primary outcomes were risk, number and length of hospitalizations due to worsening HF, and cardiovascular mortality. The secondary outcome was all-cause mortality. Baseline characteristics were collected at enrollment. Study outcomes were compared in the two groups by applying Chi-square and Fisher's exact tests. Logistic regression model was applied to assess both hospitalizations and cardiovascular mortality.
Results: A total of 111 patients were studied, 37 (33.94%) ivabradine group and 74 (66.67%) non-ivabradine group. Risk of hospitalization was lower in Ivabradine group compared to non-Ivabradine group (odds ratio: 0.43, 95% confidence interval [CI]: 0.16–1.015, P = 0.094). Average length of hospitalization in ivabradine and non-ivabradine groups was 12.54 and 8.91 days, respectively (incidence rate ratio [IRR]: 1.63, 95% CI: 0.79–3.38, P = 0.187). Compared to non-ivabradine, ivabradine patients had lower number of hospitalizations (IRR: 1.13, 95% CI: 0.61–2.11, P = 0.694). Death rate in both ivabradine and non-ivabradine groups was 3.
Conclusions: Ivabradine along with GDMT reduces the risk of hospitalization due to worsening HF symptoms. Ivabradine had no significant effect on cardiovascular mortality and all-cause mortality. HFrEF non-Arabs patients have lower risk, number and length of hospitalization, and mortality compared to Arabs. |
| first_indexed | 2024-12-20T22:51:50Z |
| format | Article |
| id | doaj.art-63baa01196044ba2b6596bbdf7a642fd |
| institution | Directory Open Access Journal |
| issn | 1995-705X |
| language | English |
| last_indexed | 2024-12-20T22:51:50Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Heart Views |
| spelling | doaj.art-63baa01196044ba2b6596bbdf7a642fd2022-12-21T19:24:14ZengWolters Kluwer Medknow PublicationsHeart Views1995-705X2021-01-0122316517310.4103/HEARTVIEWS.HEARTVIEWS_23_20The effect of ivabradine on hospitalization of heart failure patients: A retrospective cohort studySara Al-BalushiMohammed Fasihul AlamAbdul Rehman AbidAmal SharfiBackground: Ivabradine is recommended in heart failure (HF) patients to reduce cardiovascular death and hospitalization due to worsening of HF symptoms. Aims and Objectives: To study the effect of Ivabradine in addition to guideline-directed medical therapy (GDMT) in a group of HF patients with HR more than 70 bpm, HF with reduced ejection fraction (HFrEF) left ventricular ejection fraction (LVEF ≤ 40%), and New York Heart Association class II-IV. Methods: The study was conducted at Heart Hospital, Hamad Medical Corporation, Qatar. HF patients with age > 18 years, LVEF ≤40%, on GDMT, and HR of ≥70 bpm were included. The study population was divided into two groups: ivabradine group and non-ivabradine group. The primary outcomes were risk, number and length of hospitalizations due to worsening HF, and cardiovascular mortality. The secondary outcome was all-cause mortality. Baseline characteristics were collected at enrollment. Study outcomes were compared in the two groups by applying Chi-square and Fisher's exact tests. Logistic regression model was applied to assess both hospitalizations and cardiovascular mortality. Results: A total of 111 patients were studied, 37 (33.94%) ivabradine group and 74 (66.67%) non-ivabradine group. Risk of hospitalization was lower in Ivabradine group compared to non-Ivabradine group (odds ratio: 0.43, 95% confidence interval [CI]: 0.16–1.015, P = 0.094). Average length of hospitalization in ivabradine and non-ivabradine groups was 12.54 and 8.91 days, respectively (incidence rate ratio [IRR]: 1.63, 95% CI: 0.79–3.38, P = 0.187). Compared to non-ivabradine, ivabradine patients had lower number of hospitalizations (IRR: 1.13, 95% CI: 0.61–2.11, P = 0.694). Death rate in both ivabradine and non-ivabradine groups was 3. Conclusions: Ivabradine along with GDMT reduces the risk of hospitalization due to worsening HF symptoms. Ivabradine had no significant effect on cardiovascular mortality and all-cause mortality. HFrEF non-Arabs patients have lower risk, number and length of hospitalization, and mortality compared to Arabs.http://www.heartviews.org/article.asp?issn=1995-705X;year=2021;volume=22;issue=3;spage=165;epage=173;aulast=Al-Balushicardiovascular diseaseheart failurehospitalizationivabradine |
| spellingShingle | Sara Al-Balushi Mohammed Fasihul Alam Abdul Rehman Abid Amal Sharfi The effect of ivabradine on hospitalization of heart failure patients: A retrospective cohort study Heart Views cardiovascular disease heart failure hospitalization ivabradine |
| title | The effect of ivabradine on hospitalization of heart failure patients: A retrospective cohort study |
| title_full | The effect of ivabradine on hospitalization of heart failure patients: A retrospective cohort study |
| title_fullStr | The effect of ivabradine on hospitalization of heart failure patients: A retrospective cohort study |
| title_full_unstemmed | The effect of ivabradine on hospitalization of heart failure patients: A retrospective cohort study |
| title_short | The effect of ivabradine on hospitalization of heart failure patients: A retrospective cohort study |
| title_sort | effect of ivabradine on hospitalization of heart failure patients a retrospective cohort study |
| topic | cardiovascular disease heart failure hospitalization ivabradine |
| url | http://www.heartviews.org/article.asp?issn=1995-705X;year=2021;volume=22;issue=3;spage=165;epage=173;aulast=Al-Balushi |
| work_keys_str_mv | AT saraalbalushi theeffectofivabradineonhospitalizationofheartfailurepatientsaretrospectivecohortstudy AT mohammedfasihulalam theeffectofivabradineonhospitalizationofheartfailurepatientsaretrospectivecohortstudy AT abdulrehmanabid theeffectofivabradineonhospitalizationofheartfailurepatientsaretrospectivecohortstudy AT amalsharfi theeffectofivabradineonhospitalizationofheartfailurepatientsaretrospectivecohortstudy AT saraalbalushi effectofivabradineonhospitalizationofheartfailurepatientsaretrospectivecohortstudy AT mohammedfasihulalam effectofivabradineonhospitalizationofheartfailurepatientsaretrospectivecohortstudy AT abdulrehmanabid effectofivabradineonhospitalizationofheartfailurepatientsaretrospectivecohortstudy AT amalsharfi effectofivabradineonhospitalizationofheartfailurepatientsaretrospectivecohortstudy |